{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:21:56Z","timestamp":1787869316813,"version":"build-2784847793"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372650"],"award-info":[{"award-number":["82372650"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["2022A1515012508"],"award-info":[{"award-number":["2022A1515012508"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acquired resistance to sorafenib remains a major obstacle in the treatment of advanced hepatocellular carcinoma (HCC). While inducing ferroptosis represents a promising strategy to overcome this resistance, the specific molecular drivers underlying ferroptosis evasion in this context remain poorly defined. Here, we identified Aurora Kinase A (AURKA) as a central, actionable regulator of ferroptosis resistance in sorafenib-resistant HCC. AURKA was significantly upregulated in resistant cells and clinical specimens, which correlated with a suppressed ferroptotic state. Mechanistically, we discovered that AURKA directly interacted with and phosphorylated the ferritinophagy receptor NCOA4 at specific serine residues (S186\/S234\/S492), thereby competitively disrupting the NCOA4-FTH1 complex. This disruption inhibited ferritinophagic degradation of FTH1, stabilized the iron-storage protein, and limited the intracellular labile iron pool required for ferroptosis execution. Genetic or pharmacological inhibition of AURKA restored NCOA4-mediated ferritinophagy, synergized with ferroptosis inducers (sorafenib or IKE), and potently suppressed tumor growth both in vitro and in vivo. Clinically, high co-expression of AURKA and FTH1 predicted an unfavorable prognosis of HCC patients. Our study delineated the first direct link between AURKA kinase activity and the ferritinophagy machinery, establishing the AURKA-NCOA4-FTH1 axis as a master regulator of ferroptosis resistance in sorafenib-resistant HCC. These findings provide both a novel prognostic biomarker and a mechanistically grounded therapeutic strategy to overcome acquired resistance.<\/jats:p>","DOI":"10.1038\/s41419-026-08774-2","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:25:44Z","timestamp":1776990344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Wancui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-8231","authenticated-orcid":false,"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-1500","authenticated-orcid":false,"given":"Wuguo","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8774_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u2013263.","journal-title":"CA Cancer J Clin"},{"key":"8774_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68:723\u2013750.","journal-title":"Hepatology"},{"key":"8774_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3350\/cmh.2022.0402","volume":"29","author":"D Xie","year":"2022","unstructured":"Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2022;29:206\u2013216.","journal-title":"Clin Mol Hepatol"},{"key":"8774_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22:977\u2013990.","journal-title":"Lancet Oncol"},{"key":"8774_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2021","unstructured":"Yau T, Park J-W, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021;23:77\u201390.","journal-title":"Lancet Oncol"},{"key":"8774_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u2013390.","journal-title":"N Engl J Med"},{"key":"8774_CR7","doi-asserted-by":"crossref","unstructured":"Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30;1-15.","DOI":"10.3350\/cmh.2023.0125"},{"key":"8774_CR8","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1097\/JS9.0000000000002294","volume":"111","author":"C Huang","year":"2025","unstructured":"Huang C, Li Y, Zhang F, Zhang C, Ding Z. Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. Int J Surg. 2025;111:2990\u20133005.","journal-title":"Int J Surg"},{"key":"8774_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1\u03b2 in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6:190.","journal-title":"Signal Transduct Target Ther"},{"key":"8774_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101052","volume":"73","author":"S-H Hao","year":"2024","unstructured":"Hao S-H, Ma X-D, Xu L, Xie J-D, Feng Z-H, Chen J-W, et al. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resistance Updat. 2024;73:101052.","journal-title":"Drug Resistance Updat"},{"key":"8774_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302025","volume":"10","author":"Y Liao","year":"2023","unstructured":"Liao Y, Liu Y, Yu C, Lei Q, Cheng J, Kong W, et al. HSP90\u03b2 impedes STUB1-induced ubiquitination of YTHDF2 to drive sorafenib resistance in hepatocellular carcinoma. Adv Sci (Weinh). 2023;10:e2302025.","journal-title":"Adv Sci (Weinh)"},{"key":"8774_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u20131072.","journal-title":"Cell"},{"key":"8774_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7:286.","journal-title":"Signal Transduct Target Ther"},{"key":"8774_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin H-L, Huang Z-J, Lin Z-T, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.","journal-title":"Cell Death Dis"},{"key":"8774_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s11658-021-00271-y","volume":"26","author":"D Fu","year":"2021","unstructured":"Fu D, Wang C, Yu L, Yu R. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2\/Keap1\/xCT signaling. Cell Mol Biol Lett. 2021;26:26.","journal-title":"Cell Mol Biol Lett"},{"key":"8774_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u2013282.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8774_CR17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare J-C, Mazi\u00e8re J-C, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133:1732\u20131742.","journal-title":"Int J Cancer"},{"key":"8774_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27452-9","volume":"12","author":"F Yao","year":"2021","unstructured":"Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, et al. A targetable LIFR-NF-\u03baB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun. 2021;12:7333.","journal-title":"Nat Commun"},{"key":"8774_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154668","volume":"111","author":"C Yang","year":"2023","unstructured":"Yang C, Lu T, Liu M, Yuan X, Li D, Zhang J, et al. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib. Phytomedicine. 2023;111:154668.","journal-title":"Phytomedicine"},{"key":"8774_CR20","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114351","volume":"13","author":"R Gao","year":"2021","unstructured":"Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, et al. YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13:e14351.","journal-title":"EMBO Mol Med"},{"key":"8774_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41589-019-0408-1","volume":"15","author":"M Conrad","year":"2019","unstructured":"Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15:1137\u20131147.","journal-title":"Nat Chem Biol"},{"key":"8774_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","volume":"32","author":"J Zheng","year":"2020","unstructured":"Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32:920\u2013937.","journal-title":"Cell Metab"},{"key":"8774_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","volume":"25","author":"B Galy","year":"2023","unstructured":"Galy B, Conrad M, Muckenthaler M. Mechanisms controlling cellular and systemic iron homeostasis. Nat Rev Mol Cell Biol. 2023;25:133\u2013155.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8774_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature13148","volume":"509","author":"JD Mancias","year":"2014","unstructured":"Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509:105\u2013109.","journal-title":"Nature"},{"key":"8774_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","volume":"12","author":"W Hou","year":"2016","unstructured":"Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425\u20131428.","journal-title":"Autophagy"},{"key":"8774_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021\u20131032.","journal-title":"Cell Res"},{"key":"8774_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/ncb3053","volume":"16","author":"WE Dowdle","year":"2014","unstructured":"Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014;16:1069\u20131079.","journal-title":"Nat Cell Biol"},{"key":"8774_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102451","volume":"56","author":"K Li","year":"2022","unstructured":"Li K, Chen B, Xu A, Shen J, Li K, Hao K, et al. TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells. Redox Biol. 2022;56:102451.","journal-title":"Redox Biol"},{"key":"8774_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jare.2024.09.027","volume":"74","author":"G Huang","year":"2024","unstructured":"Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J Adv Res. 2024;74:589\u2013607.","journal-title":"J Adv Res"},{"key":"8774_CR30","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1158\/2159-8290.CD-22-0043","volume":"12","author":"N Santana-Codina","year":"2022","unstructured":"Santana-Codina N, Del Rey MQ, Kapner KS, Zhang H, Gikandi A, Malcolm C, et al. NCOA4-mediated ferritinophagy is a pancreatic cancer dependency via maintenance of iron bioavailability for iron-sulfur cluster proteins. Cancer Discov. 2022;12:2180\u20132197.","journal-title":"Cancer Discov"},{"key":"8774_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","volume":"70","author":"AS Nikonova","year":"2012","unstructured":"Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2012;70:661\u2013687.","journal-title":"Cell Mol Life Sci"},{"key":"8774_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13641","volume":"57","author":"L Grisetti","year":"2024","unstructured":"Grisetti L, Garcia CJC, Saponaro AA, Tiribelli C, Pascut D. The role of Aurora kinase A in hepatocellular carcinoma: unveiling the intriguing functions of a key but still underexplored factor in liver cancer. Cell Prolif. 2024;57:e13641.","journal-title":"Cell Prolif"},{"key":"8774_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"8774_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/med.21399","volume":"36","author":"M Yan","year":"2016","unstructured":"Yan M, Wang C, He B, Yang M, Tong M, Long Z, et al. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med. Res. Rev. 2016;36:1036\u20131079.","journal-title":"Med. Res. Rev"},{"key":"8774_CR35","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","volume":"17","author":"MG Manfredi","year":"2011","unstructured":"Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011;17:7614\u20137624.","journal-title":"Clin Cancer Res"},{"key":"8774_CR36","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G G\u00f6rg\u00fcn","year":"2010","unstructured":"G\u00f6rg\u00fcn G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115:5202\u20135213.","journal-title":"Blood"},{"key":"8774_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","volume":"32","author":"JW Friedberg","year":"2013","unstructured":"Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2013;32:44\u201350.","journal-title":"J Clin Oncol"},{"key":"8774_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.18.00899","volume":"37","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, \u00d6zcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, et al. Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019;37:613\u2013623.","journal-title":"J Clin Oncol"},{"key":"8774_CR39","doi-asserted-by":"publisher","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","volume":"5","author":"G Falchook","year":"2019","unstructured":"Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, et al. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2019;5:e183773.","journal-title":"JAMA Oncol"},{"key":"8774_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.871512","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li Z, Cao Q, Guan H, Mao L, Zhao M. Ferroptosis-related gene signatures in neuroblastoma associated with prognosis. Front Cell Dev Biol. 2022;10:871512.","journal-title":"Front Cell Dev Biol"},{"key":"8774_CR41","doi-asserted-by":"crossref","unstructured":"Jia X, Tian J, Fu Y, Wang Y, Yang Y, Zhang M et al. Identification of AURKA as a Biomarker Associated with Cuproptosis and Ferroptosis in HNSCC. Int J Mol Sci. 2024;25;4372.","DOI":"10.3390\/ijms25084372"},{"key":"8774_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110471","volume":"378","author":"L Luo","year":"2023","unstructured":"Luo L, Chen X, Huang F. Machine learning revealed ferroptosis features and ferroptosis-related gene-based immune microenvironment in lung adenocarcinoma. Chem Biol Interact. 2023;378:110471.","journal-title":"Chem Biol Interact"},{"key":"8774_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1083\/jcb.200503023","volume":"170","author":"K Kinoshita","year":"2005","unstructured":"Kinoshita K, Noetzel TL, Pelletier L, Mechtler K, Drechsel DN, Schwager A, et al. Aurora A phosphorylation of TACC3\/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol. 2005;170:1047\u20131055.","journal-title":"J Cell Biol"},{"key":"8774_CR44","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1083\/jcb.200504097","volume":"170","author":"TP Barros","year":"2005","unstructured":"Barros TP, Kinoshita K, Hyman AA, Raff JW. Aurora A activates D-TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules. J Cell Biol. 2005;170:1039\u20131046.","journal-title":"J Cell Biol"},{"key":"8774_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","volume":"15","author":"T Otto","year":"2009","unstructured":"Otto T, Horn S, Brockmann M, Eilers U, Sch\u00fcttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15:67\u201378.","journal-title":"Cancer Cell"},{"key":"8774_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41416-024-02649-z","volume":"130","author":"A Rio-Vilari\u00f1o","year":"2024","unstructured":"Rio-Vilari\u00f1o A, Cenigaonandia-Campillo A, Garc\u00eda-Bautista A, Mateos-G\u00f3mez PA, Schlaepfer MI, Del Puerto-Nevado L, et al. Inhibition of the AURKA\/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. Br J Cancer. 2024;130:1402\u20131413.","journal-title":"Br J Cancer"},{"key":"8774_CR47","doi-asserted-by":"crossref","unstructured":"Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;26;623-633.","DOI":"10.1016\/j.chembiol.2019.01.008"},{"key":"8774_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41419-024-06485-0","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, Hu J, Xiong X, Chen H, Lin B, Chen Y, et al. AURKA inhibition induces Ewing\u2019s sarcoma apoptosis and ferroptosis through NPM1\/YAP1 axis. Cell Death Dis. 2024;15:99.","journal-title":"Cell Death Dis"},{"key":"8774_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17386","volume":"9","author":"S Li","year":"2023","unstructured":"Li S, Qi Y, Yu J, Hao Y, Xu L, Ding X, et al. Aurora kinase A regulates cancer-associated RNA aberrant splicing in breast cancer. Heliyon. 2023;9:e17386.","journal-title":"Heliyon"},{"key":"8774_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202409329","volume":"36","author":"L Lei","year":"2024","unstructured":"Lei L, Yuan J, Dai Z, Xiang S, Tu Q, Cui X, et al. Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson\u2019s Disease Therapy. Adv Mater. 2024;36:e2409329.","journal-title":"Adv Mater"},{"key":"8774_CR51","doi-asserted-by":"crossref","unstructured":"Mancias JD, Pontano Vaites L, Nissim S, Biancur DE, Kim AJ, Wang X et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife. 2015;4;e10308.","DOI":"10.7554\/eLife.10308"},{"key":"8774_CR52","doi-asserted-by":"publisher","first-page":"11409","DOI":"10.1002\/anie.201704654","volume":"56","author":"JAH Gilburt","year":"2017","unstructured":"Gilburt JAH, Sarkar H, Sheldrake P, Blagg J, Ying L, Dodson CA. Dynamic Equilibrium of the AuroraA Kinase Activation Loop Revealed by Single-Molecule Spectroscopy. Angew Chem Int Ed Engl. 2017;56:11409\u201311414.","journal-title":"Angew Chem Int Ed Engl"},{"key":"8774_CR53","doi-asserted-by":"crossref","unstructured":"Musavizadeh Z, Grottesi A, Guarguaglini G, Paiardini A. Phosphorylation, Mg-ADP, and Inhibitors Differentially Shape the Conformational Dynamics of the A-Loop of Aurora-A. Biomolecules. 2021;11;567.","DOI":"10.3390\/biom11040567"},{"key":"8774_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol (Baltim, Md). 2018;68:723\u2013750.","journal-title":"Hepatol (Baltim, Md)"},{"key":"8774_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188382","volume":"1874","author":"Z Cheng","year":"2020","unstructured":"Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 2020;1874:188382.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8774_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102610","volume":"51","author":"S Xia","year":"2020","unstructured":"Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610.","journal-title":"EBioMedicine"},{"key":"8774_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189310","volume":"1880","author":"W Zhang","year":"2025","unstructured":"Zhang W, Hong X, Xiao Y, Wang H, Zeng X. Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2025;1880:189310.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8774_CR58","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng J, Sato M, Mishima E, Sato H, Proneth B, Conrad M. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12:698.","journal-title":"Cell Death Dis"},{"key":"8774_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u2013442.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8774_CR60","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.devcel.2025.02.004","volume":"60","author":"WC Lee","year":"2025","unstructured":"Lee WC, Dixon SJ. Mechanisms of ferroptosis sensitization and resistance. Dev Cell. 2025;60:982\u2013993.","journal-title":"Dev Cell"},{"key":"8774_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbrc.2017.03.075","volume":"486","author":"C Chen","year":"2017","unstructured":"Chen C, Song G, Xiang J, Zhang H, Zhao S, Zhan Y. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017;486:514\u2013520.","journal-title":"Biochem Biophys Res Commun"},{"key":"8774_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2282184","volume":"56","author":"M Chen","year":"2024","unstructured":"Chen M, Zhu H, Li J, Luo D, Zhang J, Liu W, et al. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA. Ann Med. 2024;56:2282184.","journal-title":"Ann Med"},{"key":"8774_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1162563","volume":"14","author":"J Hu","year":"2023","unstructured":"Hu J, Song F, Kang W, Xia F, Song Z, Wang Y, et al. Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma. Front Pharm. 2023;14:1162563.","journal-title":"Front Pharm"},{"key":"8774_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84607-6","volume":"15","author":"TT Chung","year":"2025","unstructured":"Chung TT, Piao Z, Lee SJ. Identification of ferroptosis-related signature predicting prognosis and therapeutic responses in pancreatic cancer. Sci Rep. 2025;15:75.","journal-title":"Sci Rep"},{"key":"8774_CR65","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1080\/15548627.2023.2170960","volume":"19","author":"H Wu","year":"2023","unstructured":"Wu H, Liu Q, Shan X, Gao W, Chen Q. ATM orchestrates ferritinophagy and ferroptosis by phosphorylating NCOA4. Autophagy. 2023;19:2062\u20132077.","journal-title":"Autophagy"},{"key":"8774_CR66","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1016\/j.apsb.2021.03.036","volume":"11","author":"N Kong","year":"2021","unstructured":"Kong N, Chen X, Feng J, Duan T, Liu S, Sun X, et al. Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B. 2021;11:4045\u20134054.","journal-title":"Acta Pharm Sin B"},{"key":"8774_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101915","volume":"6","author":"Y Liu","year":"2025","unstructured":"Liu Y, Sun Q, Guo J, Yan L, Yan Y, Gong Y, et al. Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2025;6:101915.","journal-title":"Cell Rep Med"},{"key":"8774_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70246","volume":"15","author":"Z-W Duan","year":"2025","unstructured":"Duan Z-W, Wang W-T, Wang Y, Wang R, Hua W, Shang C-Y, et al. SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma. Clin Transl Med. 2025;15:e70246.","journal-title":"Clin Transl Med"},{"key":"8774_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02030-x","volume":"23","author":"X-Y Zhang","year":"2024","unstructured":"Zhang X-Y, Li S-S, Gu Y-R, Xiao L-X, Ma X-Y, Chen X-R, et al. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p\/NUPR1\/FTH1 axis. Mol Cancer. 2024;23:113.","journal-title":"Mol Cancer"},{"key":"8774_CR70","first-page":"23","volume":"13","author":"R Zhang","year":"2021","unstructured":"Zhang R, Pan T, Xiang Y, Zhang M, Xie H, Liang Z, et al. Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19\/miR-19b-3p\/FTH1 axis. Bioact Mater. 2021;13:23\u201336.","journal-title":"Bioact Mater"},{"key":"8774_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103137","volume":"72","author":"Y Ye","year":"2024","unstructured":"Ye Y, Xu L, Zhang L, Zhao P, Cai W, Fu G, et al. Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis. Redox Biol. 2024;72:103137.","journal-title":"Redox Biol"},{"key":"8774_CR72","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acscentsci.0c01592","volume":"7","author":"Y Fang","year":"2021","unstructured":"Fang Y, Chen X, Tan Q, Zhou H, Xu J, Gu Q. Inhibiting Ferroptosis through Disrupting the NCOA4-FTH1 Interaction: A New Mechanism of Action. ACS Cent Sci. 2021;7:980\u2013989.","journal-title":"ACS Cent Sci"},{"key":"8774_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13621","volume":"57","author":"J-Y Li","year":"2024","unstructured":"Li J-Y, Feng Y-H, Li Y-X, He P-Y, Zhou Q-Y, Tian Y-P, et al. Ferritinophagy: A novel insight into the double-edged sword in ferritinophagy-ferroptosis axis and human diseases. Cell Prolif. 2024;57:e13621.","journal-title":"Cell Prolif"},{"key":"8774_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1731","volume":"16","author":"C Larrue","year":"2024","unstructured":"Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Sci Transl Med. 2024;16:eadk1731.","journal-title":"Sci Transl Med"},{"key":"8774_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48433-8","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Hu Q, Chen Y, Huang X, Feng Y, Shi Y, et al. Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Nat Commun. 2024;15:4195.","journal-title":"Nat Commun"},{"key":"8774_CR76","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1080\/15548627.2021.1911016","volume":"17","author":"X Qin","year":"2021","unstructured":"Qin X, Zhang J, Wang B, Xu G, Yang X, Zou Z, et al. Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells. Autophagy. 2021;17:4266\u20134285.","journal-title":"Autophagy"},{"key":"8774_CR77","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41420-023-01753-y","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang J, Wu N, Peng M, Oyang L, Jiang X, Peng Q, et al. Ferritinophagy: research advance and clinical significance in cancers. Cell Death Discov. 2023;9:463.","journal-title":"Cell Death Discov"},{"key":"8774_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402671","volume":"11","author":"X Wang","year":"2024","unstructured":"Wang X, Xu L, Meng Y, Chen F, Zhuang J, Wang M, et al. FOXO1-NCOA4 Axis Contributes to Cisplatin-Induced Cochlea Spiral Ganglion Neuron Ferroptosis via Ferritinophagy. Adv Sci (Weinh). 2024;11:e2402671.","journal-title":"Adv Sci (Weinh)"},{"key":"8774_CR79","doi-asserted-by":"publisher","first-page":"22240","DOI":"10.1021\/acsnano.3c01199","volume":"17","author":"Y Gao","year":"2023","unstructured":"Gao Y, Tong M, Wong T-L, Ng K-Y, Xie Y-N, Wang Z, et al. Long noncoding RNA URB1-antisense RNA 1 (AS1) suppresses sorafenib-induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation. ACS Nano. 2023;17:22240\u201322258.","journal-title":"ACS Nano"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08774-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:53:00Z","timestamp":1780631580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8774"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08774-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments in this study were approved by the Experimental Animal Ethics Committee of Sun Yat-sen University Cancer Center(L102042023050L). The handling and processing of patient tumor samples were done in accordance with Ethics Committee of Sun Yat-sen University Cancer Center (SL-B2022-724-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"540"}}